Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions.

[1]  Thomas L Klausen,et al.  Radioactive Seed Localization or Wire-guided Localization of Nonpalpable Invasive and In Situ Breast Cancer: A Randomized, Multicenter, Open-label Trial , 2017, Annals of surgery.

[2]  Ahmed Kamel,et al.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  T. Das,et al.  Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4+ migrating cancer stem cells , 2016, Oncogene.

[4]  L. Irwig,et al.  The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis , 2016, Annals of Surgical Oncology.

[5]  L. Strobbe,et al.  Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy , 2016, Breast Cancer Research and Treatment.

[6]  T. Julian,et al.  Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial , 2016, The Lancet.

[7]  J. Cuzick,et al.  Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial , 2016, The Lancet.

[8]  E. Hwang,et al.  Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. , 2015, Journal of the National Cancer Institute.

[9]  M. Morrow,et al.  Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. , 2015, Annals of surgery.

[10]  Ping Sun,et al.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. , 2015, JAMA oncology.

[11]  K. Hess,et al.  Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. , 2015, Endocrinology.

[12]  N. Houssami,et al.  Meta‐analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ , 2015, The British journal of surgery.

[13]  Graham A. Colditz,et al.  Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology , 2015 .

[14]  N. Bundred,et al.  Molecular phenotypes of DCIS predict overall and invasive recurrence. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Kuerer,et al.  Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? , 2015, Annals of Surgical Oncology.

[16]  Barbara L. Smith,et al.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. O’Malley,et al.  Nuclear receptor modulation – Role of coregulators in selective estrogen receptor modulator (SERM) actions , 2014, Steroids.

[18]  P. Drew,et al.  Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker. , 2014, International journal of surgery.

[19]  Qun Zhou,et al.  Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer , 2014, Oncogene.

[20]  K. Sandelin,et al.  Preoperative MRI of the Breast (POMB) Influences Primary Treatment in Breast Cancer: A Prospective, Randomized, Multicenter Study , 2014, World Journal of Surgery.

[21]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[22]  Seema A Khan,et al.  Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Morris,et al.  Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation , 2014, Annals of Surgical Oncology.

[24]  W. McCaskill-Stevens,et al.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 , 2013, Breast Cancer Research and Treatment.

[25]  T. Sørlie,et al.  Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study , 2013, BMC Cancer.

[26]  S. Noguchi,et al.  Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells , 2013, Oncology.

[27]  Eun Sook Ko,et al.  Sonographic findings of pure ductal carcinoma in situ , 2013, Journal of clinical ultrasound : JCU.

[28]  M. Silverstein,et al.  DCIS Treated with Excision Alone Using the National Comprehensive Cancer Network (NCCN) Guidelines , 2013, Annals of Surgical Oncology.

[29]  G. Wishart,et al.  Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. , 2013, The Lancet. Oncology.

[30]  E. Brogi,et al.  Ductal Carcinoma In Situ: Morphology-Based Knowledge and Molecular Advances , 2013, Advances in anatomic pathology.

[31]  N. Hansen,et al.  Effect of MRI on the Management of Ductal Carcinoma In Situ of the Breast , 2013, Annals of Surgical Oncology.

[32]  S. Fletcher,et al.  Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ , 2013, Breast Cancer Research and Treatment.

[33]  A. Bleyer,et al.  Effect of three decades of screening mammography on breast-cancer incidence. , 2012, The New England journal of medicine.

[34]  S. Mclaughlin,et al.  The Role of Preoperative Bilateral Breast Magnetic Resonance Imaging in Patient Selection for Partial Breast Irradiation in Ductal Carcinoma In Situ , 2012, International journal of surgical oncology.

[35]  H. Chu,et al.  Network meta-analysis of margin threshold for women with ductal carcinoma in situ. , 2012, Journal of the National Cancer Institute.

[36]  Gustavo Werutsky,et al.  Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. , 2012, The Lancet. Oncology.

[37]  K. Hunt,et al.  Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer , 2012, Cancer.

[38]  T. Julian,et al.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Giuliano,et al.  Preoperative Breast MRI in the Surgical Treatment of Ductal Carcinoma In Situ , 2012, The breast journal.

[40]  R. Saxena,et al.  ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective , 2012, Medicinal research reviews.

[41]  Yan Peng,et al.  A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy , 2011, International journal of breast cancer.

[42]  S. Ciatto,et al.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. , 2011, Radiology.

[43]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[44]  C. Goldsmith,et al.  Systematic review of radioguided surgery for non-palpable breast cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[45]  Florence Le Calvez-Kelm,et al.  Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells , 2011, Epigenetics.

[46]  S. van Esser,et al.  Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. , 2011, European journal of cancer.

[47]  O. Tawfik,et al.  Grading ductal carcinoma in situ of the breast using an automated proliferation index. , 2011, Annals of clinical and laboratory science.

[48]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[49]  T. Tuttle,et al.  The Influence of Preoperative MRI on Breast Cancer Treatment , 2011, Annals of Surgical Oncology.

[50]  S. Duffy,et al.  Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease , 2010, British Journal of Cancer.

[51]  David Lane,et al.  p53 Research: the past thirty years and the next thirty years. , 2010, Cold Spring Harbor perspectives in biology.

[52]  E. Resetkova,et al.  Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey. , 2010, Pathology, research and practice.

[53]  R. Kane,et al.  Ductal carcinoma in situ: risk factors and impact of screening. , 2010, Journal of the National Cancer Institute. Monographs.

[54]  Mika Watanabe,et al.  Radiologic-pathologic correlation of ductal carcinoma in situ. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.

[55]  F M Blows,et al.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received , 2010, British Journal of Cancer.

[56]  W. Scott Comulada,et al.  Breast cancer detection: radiologists’ performance using mammography with and without automated whole-breast ultrasound , 2010, European Radiology.

[57]  G. Newstead.  MR imaging of ductal carcinoma in situ. , 2010, Magnetic resonance imaging clinics of North America.

[58]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[59]  M. Michell,et al.  Image-guided breast biopsy: state-of-the-art. , 2010, Clinical radiology.

[60]  M. Chernick,et al.  Is there a Role for MRI in the Preoperative Assessment of Patients with DCIS? , 2010, Annals of Surgical Oncology.

[61]  Monica Morrow,et al.  Locoregional treatment of primary breast cancer , 2010, Cancer.

[62]  Andrew Hanby,et al.  Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial , 2010, The Lancet.

[63]  R. Clarke,et al.  Tumor and Stem Cell Biology Cancer Research Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch 4 Receptor , 2010 .

[64]  S. Pinder,et al.  Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project , 2010, British Journal of Cancer.

[65]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[66]  Molin Wang,et al.  Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  C. Parise,et al.  Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004 , 2009, The breast journal.

[68]  K. Brandt,et al.  Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Morrow,et al.  Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. , 2009, Journal of the American College of Surgeons.

[70]  Yao‐Hua Song,et al.  CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. , 2009, Cancer letters.

[71]  M. Morrow,et al.  Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Krystyna Kiel,et al.  Breast cancer. Clinical practice guidelines in oncology. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[73]  E. Rutgers,et al.  The effect of margins on the clinical management of ductal carcinoma in situ of the breast , 2008, Journal of Surgical Oncology.

[74]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[75]  Les Irwig,et al.  Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  C. Brocker,et al.  Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily , 2008, Expert opinion on drug metabolism & toxicology.

[77]  D. Santini,et al.  259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up , 2008, Breast Cancer Research and Treatment.

[78]  Jean B. Cormack,et al.  Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. , 2008, JAMA.

[79]  G. Santamaría,et al.  Preoperative MRI of pure intraductal breast carcinoma--a valuable adjunct to mammography in assessing cancer extent. , 2008, Breast.

[80]  M. Cooper,et al.  The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ , 2008, World journal of surgical oncology.

[81]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[82]  C. D. Salcido,et al.  Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.

[83]  M. Schnall,et al.  Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[85]  Simone Schrading,et al.  MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study , 2007, The Lancet.

[86]  G. Viani,et al.  Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials , 2007, Radiation oncology.

[87]  B. Williams,et al.  Wnt Signaling, Stem Cells, and the Cellular Origin of Breast Cancer , 2007, Stem Cell Reviews.

[88]  Matthew S. Mayo,et al.  Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count , 2007, Virchows Archiv.

[89]  N. Hansen,et al.  Breast cancer: pre- and postoperative imaging for staging. , 2007, Surgical oncology clinics of North America.

[90]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[91]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[92]  C. Perou,et al.  Identification of a basal-like subtype of breast ductal carcinoma in situ. , 2007, Human pathology.

[93]  L. Koniaris,et al.  Results of 23,810 Cases of Ductal Carcinoma-in-situ , 2007, Annals of Surgical Oncology.

[94]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[95]  Irma H. Russo,et al.  The role of estrogen in the initiation of breast cancer , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[96]  P. Ascenzi,et al.  Estrogen signaling multiple pathways to impact gene transcription. , 2006, Current genomics.

[97]  C. Lehman.  Role of MRI in screening women at high risk for breast cancer , 2006, Journal of magnetic resonance imaging : JMRI.

[98]  M. J. van de Vijver,et al.  Classification of ductal carcinoma in situ by gene expression profiling , 2006, Breast Cancer Research.

[99]  H. Macdonald,et al.  Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. , 2006, American journal of surgery.

[100]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[101]  G. Dontu,et al.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.

[102]  Maria Kasper,et al.  GLI transcription factors: mediators of oncogenic Hedgehog signalling. , 2006, European journal of cancer.

[103]  R. Wells,et al.  First among equals: The cancer cell hierarchy , 2006, Leukemia & lymphoma.

[104]  L. Holmberg,et al.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening , 2006, Acta oncologica.

[105]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[106]  G. Viale,et al.  Sentinel lymph node biopsy for localised ductal carcinoma in situ? , 2005, Breast.

[107]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[108]  J. Cendan,et al.  Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ: An Evolving Approach at the University of Florida , 2005, The breast journal.

[109]  W. Dupont,et al.  The natural history of low‐grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long‐term follow‐up , 2005, Cancer.

[110]  E. Mendelson,et al.  Incorporating new imaging models in breast cancer management , 2005, Current treatment options in oncology.

[111]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[112]  David M. Berman,et al.  Tissue repair and stem cell renewal in carcinogenesis , 2004, Nature.

[113]  Uwe Fischer,et al.  The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer , 2004, European Radiology.

[114]  S. Swain,et al.  Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.

[115]  M. Gnant,et al.  High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[116]  T. Tuttle,et al.  Trends in the treatment of ductal carcinoma in situ of the breast. , 2004, Journal of the National Cancer Institute.

[117]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[118]  J. Kemper,et al.  Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[119]  R. Schulz-Wendtland,et al.  Stereotactic vacuum‐assisted breast biopsy in 2874 patients , 2004, Cancer.

[120]  H. Varmus,et al.  Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[121]  J. Lara,et al.  The relevance of occult axillary micrometastasis in ductal carcinoma in situ , 2003, Cancer.

[122]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[123]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[124]  J. Crowe,et al.  Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. , 2003, American journal of surgery.

[125]  M. Silverstein.  The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. , 2003, American journal of surgery.

[126]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[127]  S. Steinberg,et al.  Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy , 2003, Cancer.

[128]  Isabelle Bedrosian,et al.  Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging , 2003, Cancer.

[129]  J. Houghton.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[130]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[131]  I. Bauerfeind,et al.  EGFR, HER-2/neu, Cyclin D1, p21 and p53 in Correlation to Cell Proliferation and Steroid Hormone Receptor Status in Ductal Carcinoma in situ of the Breast , 2003, Breast Cancer Research and Treatment.

[132]  S. Shousha,et al.  Oestrogen receptor negativity as a marker for high‐grade ductal carcinoma in situ of the breast , 2003, Histopathology.

[133]  A. Nardulli,et al.  Estrogen receptor α and Sp1 regulate progesterone receptor gene expression , 2003, Molecular and Cellular Endocrinology.

[134]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[135]  A. Luini,et al.  Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. , 2003, Archives of surgery.

[136]  G. Giles,et al.  Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. , 2003, European journal of cancer.

[137]  A. Kalmes,et al.  Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. , 2003, Journal of vascular surgery.

[138]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[139]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[140]  S. Jaffer,et al.  Histologic classification of ductal carcinoma in situ , 2002, Microscopy research and technique.

[141]  D. Schultz,et al.  Effect of breast magnetic resonance imaging on the clinical management of women with early-stage breast carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[143]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[144]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[145]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[146]  I. Fentiman,et al.  Occult axillary lymph node metastases are of no prognostic significance in breast cancer , 2002, British Journal of Cancer.

[147]  A. Kiger,et al.  Stem Cell Self-Renewal Specified by JAK-STAT Activation in Response to a Support Cell Cue , 2001, Science.

[148]  S. Edge,et al.  NCCN: Breast cancer. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[149]  L. Harris,et al.  First-Line Herceptin® Monotherapy in Metastatic Breast Cancer , 2001, Oncology.

[150]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[151]  C. Klinge.  Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.

[152]  M. Bai,et al.  The in vivo cell kinetics in breast carcinogenesis , 2001, Breast Cancer Research.

[153]  M. Silverstein,et al.  Predicting Axillary Nodal Positivity in 2282 Patients with Breast Carcinoma , 2001, World Journal of Surgery.

[154]  M D Schnall,et al.  Update of breast MR imaging architectural interpretation model. , 2001, Radiology.

[155]  L Duchateau,et al.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  E. van Marck,et al.  Early distant relapse in ‘node‐negative’ breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour , 2001, The Journal of pathology.

[157]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[158]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[159]  W. P. Evans,et al.  Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. , 2001, Radiology.

[160]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[161]  R. Matsubayashi,et al.  Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. , 2000, Radiology.

[162]  R. Ullrich,et al.  Progesterone facilitates chromosome instability (aneuploidy) in p53 null , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[163]  J. Peterse,et al.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 , 2000, The Lancet.

[164]  H. Verkooijen,et al.  Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: a meta-analysis , 2000, British Journal of Cancer.

[165]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[166]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  N. Sládek.  Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. , 1999, Current pharmaceutical design.

[168]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[169]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[170]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[171]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[172]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[173]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[174]  L. Liberman,et al.  US-guided core breast biopsy: use and cost-effectiveness. , 1998, Radiology.

[175]  I. Ellis,et al.  Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. , 1998, Human pathology.

[176]  J. Bergh,et al.  Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors , 1998, International journal of cancer.

[177]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[178]  G. Farr,et al.  Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities. , 1998, Annals of surgery.

[179]  B. Delahunt,et al.  Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. , 1998, Journal of clinical pathology.

[180]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[181]  K. Hara,et al.  Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[182]  K. Korach,et al.  Mammary Gland Development and Tumorigenesis in Estrogen Receptor Knockout Mice , 1997, Journal of Mammary Gland Biology and Neoplasia.

[183]  M. Taupitz,et al.  Peripheral washout sign on contrast-enhanced MR images of the breast. , 1997, Radiology.

[184]  Y. Soini,et al.  The extent of apoptosis is inversely associated with bcl‐2 expression in premalignant and malignant breast lesions , 1997, Histopathology.

[185]  M. Lagios,et al.  Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. , 1997, Human pathology.

[186]  J. Meyer,et al.  Stereotactic breast biopsy of clustered microcalcifications with a directional, vacuum-assisted device. , 1997, Radiology.

[187]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[188]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[189]  F. Burbank.  Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. , 1997, Radiology.

[190]  R. Perry,et al.  p53 protein expression in ductal carcinoma in situ (DCIS) of the breast , 1997, Breast Cancer Research and Treatment.

[191]  M. Schnall,et al.  MR imaging of ductal carcinoma in situ. , 1997, Radiology.

[192]  R. Mansel,et al.  A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma , 1996, Histopathology.

[193]  W. P. Evans,et al.  Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. , 1996, Radiology.

[194]  J. Roth,et al.  Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. , 1996, The Journal of thoracic and cardiovascular surgery.

[195]  S. Paik,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B‐17: Five‐year observations concerning lobular carcinoma in situ , 1996, Cancer.

[196]  L D Buadu,et al.  Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. , 1996, Radiology.

[197]  M. Silverstein,et al.  A prognostic index for ductal carcinoma in situ of the breast , 1996, Cancer.

[198]  J. Coyne,et al.  Comparison of cytomorphological and architectural heterogeneity in mammographically‐detected ductal carcinoma in situ , 1996, Histopathology.

[199]  D. Brogan,et al.  Epidemiology of in situ and invasive breast cancer in women aged under 45. , 1996, British Journal of Cancer.

[200]  C. Potten,et al.  Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. , 1996, British Journal of Cancer.

[201]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[202]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[203]  S. Schnitt,et al.  bcl‐2 expression in the spectrum of preinvasive breast lesions , 1996 .

[204]  P Aspelin,et al.  Sensitivity and Specificity of MR Mammography with Histopathological Correlation in 250 Breasts , 1996, Acta radiologica.

[205]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[206]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[207]  C. Redmond,et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. , 1995, New England Journal of Medicine.

[208]  S. Edge,et al.  Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. , 1995, Radiology.

[209]  B. O’Malley,et al.  Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. , 1995, Genes & development.

[210]  I. Bleiweiss,et al.  Prognostic variables in invasive breast cancer: Contribution of comedo versus noncomedo in situ component , 1995, Annals of Surgical Oncology.

[211]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[212]  M. Silverstein,et al.  Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. , 1995, European journal of cancer.

[213]  R. Gilles,et al.  Ductal carcinoma in situ: MR imaging-histopathologic correlation. , 1995, Radiology.

[214]  N. Sneige,et al.  Ductal carcinoma in situ treated with lumpectomy and irradiation: histopathological analysis of 49 specimens with emphasis on risk factors and long term results. , 1995, Human pathology.

[215]  M. J. Silverstein,et al.  Prognostic classification of breast ductal carcinoma-in-situ , 1995, The Lancet.

[216]  F. Schmitt,et al.  Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c‐erbB‐2 protein , 1995, Cancer.

[217]  Joseph Costantino,et al.  Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17. Intraductal carcinoma (ductal carcinoma in situ) , 1995, Cancer.

[218]  P. Viehweg,et al.  Sensitivity of contrast-enhanced MR imaging of the breast. , 1994, Magnetic resonance imaging clinics of North America.

[219]  W. Gregory,et al.  The classification of ductal carcinoma in situ and its association with biological markers. , 1994, Seminars in diagnostic pathology.

[220]  J. Hendriks,et al.  Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. , 1994, Seminars in diagnostic pathology.

[221]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[222]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[223]  Y. Yarden,et al.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.

[224]  O Lucidarme,et al.  Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. , 1994, Radiology.

[225]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[226]  W. Dupont,et al.  P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment , 1994, Cancer.

[227]  M D Schnall,et al.  Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. , 1994, Radiology.

[228]  D N Poller,et al.  Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[229]  B. Gusterson,et al.  Expression of BCL‐2 in the developing human fetal and infant breast , 1994, Histopathology.

[230]  M. Bur,et al.  Estrogen and progesterone receptor detection in neoplastic and non-neoplastic thyroid tissues. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[231]  I. Ellis,et al.  Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. , 1993, British Journal of Cancer.

[232]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[233]  S E Harms,et al.  MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. , 1993, Radiology.

[234]  I. Ellis,et al.  p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. , 1993, Human pathology.

[235]  J. J. Gisvold,et al.  Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions. , 1993, Mayo Clinic proceedings.

[236]  K. Zedeler,et al.  Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. , 1992, The American journal of surgical pathology.

[237]  K. Zedeler,et al.  Lobular Carcinoma In Situ of the Female Breast , 1992 .

[238]  A. Murray,et al.  Creative blocks: cell-cycle checkpoints and feedback controls , 1992, Nature.

[239]  J. Connolly,et al.  Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype. , 1992, AJR. American journal of roentgenology.

[240]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[241]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[242]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[243]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[244]  J. Killeen,et al.  DNA analysis of ductal carcinoma In situ of the breast. A comparison with histologic features , 1991, Cancer.

[245]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[246]  D. Lane,et al.  Expression of p53 protein in infiltrating and in‐situ breast carcinomas , 1991, The Journal of pathology.

[247]  K. Hopper,et al.  Nonpalpable breast lesions: stereotactic automated large-core biopsies. , 1991, Radiology.

[248]  D. Barnes,et al.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ , 1991, Breast Cancer Research and Treatment.

[249]  Y. Yarden,et al.  Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. , 1990, Biochemistry.

[250]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[251]  J. Bártková,et al.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. , 1990, Human pathology.

[252]  M. Lagios.  Duct carcinoma in situ. Pathology and treatment. , 1990, The Surgical clinics of North America.

[253]  M. Greene,et al.  Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.

[254]  S. Ashley,et al.  Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis , 1990, The Journal of pathology.

[255]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[256]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[257]  J. Hendriks,et al.  Extent, distribution, and mammographic/ histological correlations of breast ductal carcinoma in situ , 1990, The Lancet.

[258]  J T Ennis,et al.  Breast disease: tissue characterization with Gd-DTPA enhancement profiles. , 1990, Radiology.

[259]  D. Giri,et al.  Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study , 1989, Histopathology.

[260]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[261]  S. Heywang,et al.  MR imaging of the breast with Gd-DTPA: use and limitations. , 1989, Radiology.

[262]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[263]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[264]  S. Feig,et al.  Heterogeneity of intraductai carcinoma of the breast , 1989 .

[265]  M. Lagios,et al.  Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence , 1989, Cancer.

[266]  I. Ellis,et al.  Immunocytochemical localization of estrogen receptor in human breast tissue. , 1988, Cancer research.

[267]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[268]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[269]  Turner Da,et al.  Nuclear magnetic resonance in the diagnosis of breast cancer , 1988 .

[270]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[271]  M. J. van de Vijver,et al.  Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. , 1988, Oncogene.

[272]  B. Gusterson,et al.  Immunohistochemical localization of c-erbB-2 in human breast carcinomas. , 1987, Molecular and cellular probes.

[273]  J. Lindgren,et al.  Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.

[274]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[275]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[276]  M. Isobe,et al.  Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.

[277]  S. Heywang,et al.  MR imaging of the breast using gadolinium-DTPA. , 1986, Journal of computer assisted tomography.

[278]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[279]  L. Tabár,et al.  REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.

[280]  B Fisher,et al.  Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.

[281]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[282]  A. Levine,et al.  Characterization of human p53 antigens employing primate specific monoclonal antibodies. , 1983, Virology.

[283]  Y. Taketani,et al.  Epidermal growth factor stimulates cell proliferation and inhibits functional differentiation of mouse mammary epithelial cells in culture. , 1983, Endocrinology.

[284]  V. Rotter.  p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[285]  Y. Imai,et al.  Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. , 1982, Cancer research.

[286]  D. Pim,et al.  Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. , 1982, The EMBO journal.

[287]  R. J. Ross,et al.  Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials. , 1982, Radiology.

[288]  W. Dupont,et al.  Intraductal carcinoma of the breast: Follow‐up after biopsy only , 1982, Cancer.

[289]  A. Levine,et al.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells , 1982, Cell.

[290]  A. Luini,et al.  Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in Patients with Small Cancers of the Breast , 1981 .

[291]  G. Murphy,et al.  Noninvasive Breast Carcinoma: Results of a National Survey by the American College of Surgeons , 1980, Annals of surgery.

[292]  C. Osborne,et al.  Epidermal growth factor stimulation of human breast cancer cells in culture. , 1980, Cancer research.

[293]  J. Rowley,et al.  Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. , 1979, Cancer research.

[294]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[295]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[296]  P. Rosen,et al.  Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. , 1978 .

[297]  H M Jensen,et al.  On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.

[298]  M. Black,et al.  Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer , 1972, Cancer.

[299]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[300]  Adelstein Am,et al.  Revision of the international classification of diseases. , 1971, Lancet.

[301]  Holleb Ai,et al.  Prior breast disease in patients treated for papillary carcinoma. , 1968 .

[302]  J. Elam,et al.  Rescue breathing: a modification. , 1959, Lancet.

[303]  J. Wild,et al.  Use of high-frequency ultrasonic waves for detecting changes of texture in living tissues. , 1951, Lancet.

[304]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[305]  M. Press,et al.  Molecular Oncology of Breast Cancer , 2018 .

[306]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[307]  I. Ellis,et al.  Ductal Carcinoma In Situ , 2012 .

[308]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[309]  A. Wagers,et al.  Notch signaling in the regulation of stem cell self-renewal and differentiation. , 2010, Current topics in developmental biology.

[310]  D. Simeone,et al.  Identification of human pancreatic cancer stem cells. , 2009, Methods in molecular biology.

[311]  Karel G M Moons,et al.  Meta-analysis of MR imaging in the diagnosis of breast lesions. , 2008, Radiology.

[312]  S. Pinder,et al.  Chapter 17 – Morphology of Ductal Carcinoma in situ , 2006 .

[313]  V. Eusebi,et al.  Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas , 2005, Virchows Archiv.

[314]  R. Callahan,et al.  Notch Signaling in Mammary Gland Tumorigenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[315]  W. Kaiser,et al.  High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. , 2003, The British journal of radiology.

[316]  Andrew A Renshaw,et al.  Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. , 2002, Archives of pathology & laboratory medicine.

[317]  R. Nicholson,et al.  Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. , 2002, Cancer research.

[318]  J. Baselga.  Clinical trials of Herceptin(trastuzumab). , 2001, European journal of cancer.

[319]  Y. Yarden,et al.  The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[320]  N. Bundred,et al.  Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ , 2001, Cancer.

[321]  A. Gad,et al.  Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas , 1999, Virchows Archiv.

[322]  J. Foekens,et al.  p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[323]  E A Sickles,et al.  Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. , 1997, Journal of the National Cancer Institute.

[324]  D. Page,et al.  Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions , 1994, Cancer.

[325]  J. Davies,et al.  Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U. K. National Coordinating Group for Breast Screening Pathology. , 1994, European journal of cancer.

[326]  U. Chetty,et al.  Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. , 1993, Human pathology.

[327]  E van der Schueren,et al.  Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. , 1992, Journal of the National Cancer Institute. Monographs.

[328]  A Lichter,et al.  Results of the National Cancer Institute early breast cancer trial. , 1992, Journal of the National Cancer Institute. Monographs.

[329]  E. Martinez,et al.  cis- and trans-acting elements of the estrogen-regulated vitellogenin gene B1 of Xenopus laevis. , 1989, Journal of steroid biochemistry.

[330]  M. Lagios,et al.  Mammographic detection of early breast cancer. Ten years' experience in a community hospital. , 1986, The Western journal of medicine.

[331]  L. Tabár,et al.  Basic principles of mammographic diagnosis. , 1985, Diagnostic imaging in clinical medicine.

[332]  H. Kerr,et al.  Observations on a “sentinel node” in cancer of the parotid , 1960, Cancer.